Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/27300
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSahasakul Y.
dc.contributor.authorAngkhasirisap W.
dc.contributor.authorLam-Ubol A.
dc.contributor.authorAursalung A.
dc.contributor.authorSano D.
dc.contributor.authorTakada K.
dc.contributor.authorTrachootham D.
dc.date.accessioned2022-12-14T03:17:06Z-
dc.date.available2022-12-14T03:17:06Z-
dc.date.issued2022
dc.identifier.issn20726643
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85129770023&doi=10.3390%2fnu14102023&partnerID=40&md5=5f8e3ed7067f2164e5ea21eeb5a1305e
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/27300-
dc.description.abstractMany types of cancer have metabolic alterations with increased glycolysis. Identification of alternative sweeteners that do not fuel cancer is a novel approach to cancer control. The present study aimed to investigate the effects of xylitol on tumor growth and survival of mice bearing orthotopic xenograft of tongue cancers. The results showed that partial substitution of glucose with xylitol (glucose 0.35 g plus xylitol 2.06 g/kg body weight) non-significantly reduced tumor volume, and significantly prolonged the median survival time from 19 days in the control to 30.5 days in the xylitol group. Immunohistochemical data of the tongue tissue shows significantly lower intense-to-mild staining ratios of the proliferation marker Ki-67 in the xylitol than those of the control group (p = 0.04). Furthermore, the xylitol substitution significantly reduced the expression of the rate-limiting glycolytic enzyme, phosphofructokinase-1 (PFK-1) (p = 0.03), and showed a non-significant inhibition of PFK activity. In summary, partial substitution of glucose with xylitol at the equivalent dose to human household use of 10 g/day slows down tumor proliferation and prolongs survival of mice bearing an orthotopic oral cancer xenograft, possibly through glycolytic inhibition, with minimal adverse events. The insight warrants clinical studies to confirm xylitol as a candidate sweetener in food products for cancer survivors. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
dc.languageen
dc.publisherMDPI
dc.subjectglucose
dc.subjectglycolysis
dc.subjectoral cancer
dc.subjectorthotopic xenograft model
dc.subjectPFK
dc.subjectsweetener
dc.subjectxylitol
dc.titlePartial Substitution of Glucose with Xylitol Prolongs Survival and Suppresses Cell Proliferation and Glycolysis of Mice Bearing Orthotopic Xenograft of Oral Cancer
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationJournal of Engineering Science and Technology. Vol 17, No.5 (2022), p.3424-3432
dc.identifier.doi10.3390/nu14102023
Appears in Collections:Scopus 2022

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.